Meeting
2020 ASCO Virtual Scientific Program
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
Authors
Sara M. Tolaney
Dana-Farber Cancer Institute, Boston, MA
Sara M. Tolaney , Irfan Cicin , Rafael Betancourt , Arlene Chan , Diego Kaen , Peter A. Kaufman , Suzette Delaloge , Qianying Liu , Sylvaine Cartot-Cotton , Amele Amrate , Vasiliki Pelekanou , Katharine Ellen Cuff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04059484
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS1107)
DOI
10.1200/JCO.2020.38.15_suppl.TPS1107
Abstract #
TPS1107
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu
Poster
2021 ASCO Annual Meeting
A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.
First Author: Oana Cristina Danciu
Poster
2017 Palliative and Supportive Care in Oncology Symposium
Risk of health-related quality of life events from pain and fatigue among patients with hormone receptor-positive HER-2 negative metastatic breast cancer treated with CDK 4/6 inhibitor.
First Author: Myat M. Han
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone